MUC1 was used as a target for the treatment of epithelial ovarian tumour in the included trial and for pancreatic tumour in another trial [43], but this trial was terminated prematurely without a positive outcome for RIT. The gene discussed is MUC1; the disease is pancreatic neoplasm.